Question 1

What is Sol-Gel Technologies's P/FCF ratio?

Accepted Answer

Sol-Gel Technologies (SLGL) P/FCF ratio is currently not available. When trailing twelve-month free cash flow is negative — common during heavy capex cycles or operating losses — P/FCF is reported as N/A and analysts switch to P/S or EV/EBITDA.

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for Sol-Gel Technologies?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For Sol-Gel Technologies specifically, the relevant sector benchmark is the current sector median of 19.2×.

Question 5

Why does Sol-Gel Technologies's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 6

Why is Sol-Gel Technologies's P/FCF ratio not available?

Accepted Answer

When trailing twelve-month free cash flow is negative — common during heavy capex cycles or operating losses — P/FCF is reported as N/A and analysts switch to P/S or EV/EBITDA.


2025	$117M	—	—	—	Dec 31, 2025
2024	$259M	—	—	—	Dec 31, 2024
2023	$309M	$0.00	—	—	Dec 31, 2023
2022	$1.05B	$0.00	—	—	Dec 31, 2022
2021	$1.71B	-$15.8M	—	—	Dec 31, 2021
2020	$2.23B	-$13.1M	—	—	Dec 31, 2020
2019	$3.51B	-$14.2M	—	—	Dec 31, 2019
2018	$1.14B	-$11.7M	—	—	Dec 31, 2018
2017	$2.45B	-$26M	—	—	Dec 31, 2017
2016	$2.45B	-$18.9M	—	—	Dec 31, 2016


Align Technology (ALGN)	17.8×
McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
HCA Healthcare (HCA)	14.5×
Becton, Dickinson and (BDX)	14.0×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for Sol-Gel Technologies (SLGL)

P/FCF Ratio daily chart for Sol-Gel Technologies (SLGL)

Historical P/FCF Ratio for Sol-Gel Technologies (SLGL) from 2016 to 2025

About P/FCF Ratio at Sol-Gel Technologies (SLGL)

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

Sol-Gel Technologies (SLGL) Key Financials